secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001628280-24-013888
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive appoints Abigail L. Jenkins to Board of Directors
-----------------------------------------------------------

- Ms. Jenkins appointed as Class II director effective April 1, 2024, term through 2026 annual meeting.
- Appointed to Nominating and Corporate Governance Committee; board size increased from 7 to 8 members.
- Ms. Jenkins will receive 57,000 stock options under 2018 Equity Incentive Plan, vesting in 1/3 annual increments.
- Board determined Ms. Jenkins is an independent director under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024013888/0001628280-24-013888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024013888/aqst-20240401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-013888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer